Skip to main content

Advertisement

Table 2 FEV 1 change from baseline at week 12 (day 84), ITT population

From: Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

  VI 25 mcg OD (n = 101) SAL 50 mcg BD (n = 100) Placebo (n = 95)
LS mean change from baseline (ml) 359 (41.6) 283 (41.9) 289 (42.9)
Difference vs. placebo (ml) 70 -6 NA
95% CI (-48 – 188) (-124 – 113)
P-value 0.244 0.926
  1. Values are weighted mean (SE) 0–24 hour FEV1 (ml) unless otherwise stated.
  2. ANCOVA model with covariates of baseline FEV1, region, age, sex and treatment.
  3. ANCOVA: analysis of covariates; BD: twice-daily; CI: confidence interval; FEV1: forced expiratory volume in one second; ITT: intent-to-treat; LS: least squares; n: number of patients used in analysis; NA: not applicable; OD: once-daily; SAL: salmeterol; SE: standard error; VI: vilanterol.